crossing96/oncoscreening huggingface dataset:
Comprehensive analysis of coagulation-associated gene signature in bladder cancer diagnosis, prognosis, and immunotherapy.	In recent years, research on the relationship between coagulation system abnormalities and tumor immunity has been widely reported. Bladder cancer (BC), as an immunogenic tumor, holds great promise in immunotherapy. The role of coagulation-related genes in predicting the prognosis of BC patients and the efficacy of immunotherapy remains to be explored. In this study, we utilized the TCGA data system to analyze the biological functions of coagulation-related genes (CRGs) in BC patients. Additionally, we employed multiple machine learning methods (LASSO regression, SVM-RFE regression, and random forest) to establish diagnostic and prognostic signatures for BC based on CRGs. Univariate and multivariate Cox analyses indicated that the prognostic signature is an independent risk factor. Combining risk scores and independent clinical parameters, we established a Nomogram with a C-index of 0.812. Furthermore, we applied CRGs to cluster BC patients, and significant differences were observed between the two clusters in terms of immune cell infiltration, immune cell pathway activity, and response to immunotherapy. In conclusion, we systematically analyzed the value of CRGs in the diagnosis, prognosis, and personalized treatment of BC patients.	bladder
Diagnostic Values of Serum Matrix Metalloproteinase-9 and Nuclear Matrix Protein 22 for Bladder Cancer.	BACKGROUND: This study aimed to evaluate the diagnostic value of serum matrix metalloproteinase-9 (MMP-9) and nuclear matrix protein 22 (NMP22) in patients with bladder cancer. METHODS: Patients pathologically diagnosed with bladder cancer between January 2023 and January 2024 were included as the experimental group, while healthy individuals undergoing routine physical examinations during the same period comprised the control group. Serum MMP-9 and NMP22 levels were measured via enzyme-linked immunosorbent assay. Diagnostic performance was assessed using receiver operating characteristic curves, and multivariate logistic regression was performed to determine their ability to independently predict tumor-node-metastasis (TNM) stage. RESULTS: Serum MMP-9 and NMP22 levels were significantly higher in bladder cancer patients compared to healthy controls (p < 0.001). Patients at the T stage showed significantly elevated levels compared to those at the N and M stages (p < 0.001). The areas under the curves for MMP-9, NMP22, and their combination were 0.786 (95% confidence interval (CI): 0.714-0.857), 0.785 (95% CI: 0.714-0.857), and 0.793 (95% CI: 0.725-0.862), respectively, with corresponding sensitivities of 70.00%, 72.00%, and 75.00%, and specificities of 80.00%, 78.00%, and 85.00%. Hematuria (odds ratio (OR): 3.42, 95% CI: 1.89-6.18), frequent urination (OR: 2.44, 95% CI: 1.41-4.22), urinary urgency (OR: 2.18, 95% CI: 1.19-3.99), MMP-9 (OR: 1.01, 95% CI: 1.004-1.016), and NMP22 (OR: 0.98, 95% CI: 0.97-0.99) were identified as independent predictors of TNM stage (p < 0.05). The Cancer Genome Atlas (TCGA) data further confirmed elevated MMP-9 messenger RNA (mRNA) expression in tumor tissues versus adjacent normal tissues (p < 0.001). CONCLUSIONS: Serum MMP-9 and NMP22 levels are significantly elevated in bladder cancer and correlate with TNM stage. Combined detection may improve diagnostic accuracy and clinical utility in bladder cancer diagnosis.	bladder
Clinicopathological significance of Kruppel-like factor 15 and epithelial-to-mesenchymal transition related factors in bladder cancer.	The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell death. The epithelial-to-mesenchymal transition (EMT) provides malignant cells with the adaptability and movement necessary for tumor advancement and spread, with zinc finger E-box binding homeobox 1(ZEB1) playing a pivotal role as a transcriptional factor in EMT. This investigation initially examined the association between the KLF15 protein and EMT associated transcription factors such as ZEB1, Slug, and Snail, along with marker proteins like E-cadherin and β-catenin in bladder cancer. Furthermore, we explored their connections with clinicopathological attributes and conducted prognostic analyses. Immunohistochemical techniques were utilized to ascertain the presence of KLF15 protein and EMT-associated transcription factor proteins, along with their marker proteins in 110 specimens of bladder cancer tissues. Concurrently, clinicopathological data and postoperative survival statistics were amassed. The rates of KLF15 and Slug protein expression were linked with pathological differentiation, lymphatic involvement, and pTNM staging. The protein expression rates of ZEB1, Slug, Snail, E-cadherin, and β-catenin also showed associations with lymphatic metastasis and pTNM stages. Notably, the expression of KLF15, the coexpression of KLF15 and ZEB1, and lymphatic metastasis emerged as independent prognostic indicators for the overall survival rates in bladder cancer cases. EMT enhances the risk of tumor recurrence and reduces overall survival durations in bladder cancer cases. Furthermore, KLF15 is a significant contributor to the EMT pathway in bladder cancer, primarily through its interaction with the transcription factor ZEB1. KLF15 and ZEB1 might serve as key biomarkers for metastasis and prognosis, offering potential new targets for therapeutic intervention in bladder cancer.	bladder
Changes in proteinuria and the risk of urogenital cancer in Korean men.	OBJECTIVE: This study investigates the association between changes in proteinuria and the incidence of urogenital cancer (prostate, kidney, and bladder cancer) in Korean men. METHODS: We analyzed data from 1,225,646 Korean men who underwent health check-ups in 2005-2006 and 2009. Proteinuria changes were categorized into four groups based on urine dipstick tests: persistently negative, resolved, incident, and persistent proteinuria. The relationship between these groups and the incidence of urogenital cancer over follow-up through to 2021 was assessed using multivariate Cox proportional hazards models. RESULTS: Persistent proteinuria was associated with the highest risk of urogenital cancer (hazard ratio (HR) 1.323, 95 % confidence interval (CI) 1.190-1.472), followed by incident proteinuria (HR 1.155, 95 % CI 1.096-1.217). Kidney cancer risk was elevated in persistent (HR 2.312, 95 % CI 1.853-2.885), incident (HR 1.346, 95 % CI 1.171-1.546), and resolved (HR 1.293, 95 % CI 1.066-1.568) proteinuria groups. Bladder cancer risk increased in the incident proteinuria group (HR 1.425, 95 % CI 1.289-1.576). Resolved proteinuria was linked to a reduced risk of prostate cancer (HR 0.878, 95 % CI 0.796-0.968). CONCLUSION: The incidence of urogenital cancer was significantly higher for persistent proteinuria and (to a lesser degree) incident proteinuria than for persistently negative or resolved proteinuria. The risk of kidney cancer was similar to that of urogenital cancer, while other cancers had weaker associations with proteinuria. The results highlight the importance of monitoring proteinuria regularly for urogenital cancer risk assessment.	bladder
Assessing cancer risk in firefighters in Northern Germany: a retrospective cohort study.	BACKGROUND: The aim of this study is the analysis of cancer incidence and mortality among the firefighters of the municipal fire brigade in the city of Neubrandenburg in Germany. METHODS: To asses cancer risk standardized incidence ratios and standardized mortality ratios were computed. The risk of the firefighter cohort was compared to the risk of two reference populations: the county Mecklenburg Lake District, where the city of Neubrandenburg is located, and the federal state Mecklenburg-Western Pomerania. RESULTS: Results are based on data from 100 firefighters. No statistically significant results were observed for the incidence or mortality of all cancers (ICD-10 C00-C97 without C44). The SIR and SMR for bladder cancer were significantly elevated. CONCLUSION: The overall cancer incidence and mortality among Neubrandenburg's firefighters were not higher than among the reference population. The increased incidence and mortality from bladder cancer are in line with published results, especially with the monograph by the International Agency for Research on Cancer on occupational exposure as a firefighter.	bladder
Changing Trends in Bladder Cancer Epidemiology in the Israeli Population: 1996-2016.	BACKGROUND: There is a rising incidence of bladder cancer (BC) in Israel and worldwide. BC is currently the fourth most common cancer in Israeli males. There are large variations in the incidence of BC observed in different populations, both in Israel and worldwide. OBJECTIVES: To characterize the time trends and epidemiologic profile of BC in Israel regarding various population demographics. METHODS: All cases of BC reported to the Israeli National Cancer Registry between 1996 and 2016 were included. We calculated age standardized rates for BC. Joinpoint regression analysis was used to study trends in incidence as expressed by annual percent change (APC) in incidence. RESULTS: Between 1996 and 2016, 28,953 cases of BC were diagnosed in Israel. BC rates in Jewish males peaked in 2006 and subsequently declined (APC = -1.69, P < 0.05). Between 1996 and 2011, in-situ BC rates increased for both Jewish (APC = 28.2, P < 0.05) and Arab males (APC = 16.76, P < 0.05). Invasive BC incidence in Jewish males declined from 2005 to 2016 (APC = -7.6, P< 0.05) as well as in Arab males from 2006 to 2011 (APC = -12.0, P < 0.05). CONCLUSIONS: In the past two decades, in situ BC rates have risen, while invasive BC rates have decreased. BC epidemiology mirrors lung cancer trends, which is expected as smoking is a significant risk factor for both. These trends are important to identify as they can affect clinical guidelines regarding screening in high-risk populations and health care planning.	bladder
JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.	JAVEMACS-D was an observational, retrospective study describing real-world characteristics, treatment patterns, and outcomes in patients with advanced urothelial carcinoma (aUC) treated with avelumab maintenance after first-line platinum-based chemotherapy (PBC) in Japan using a large claims database (Medical Data Vision). Between February 2021 and April 2023, 773 patients received avelumab maintenance; median age was 74 years, primary tumor site was bladder in 59.9% and renal pelvis/ureter in 42.7%, and first-line PBC was cisplatin-gemcitabine in 61.3% and carboplatin-gemcitabine in 36.4%. Avelumab maintenance started in 2021 in 289 patients (37.4%) and in 2022 or later in 484 (62.6%). At data cutoff (October 2023), median follow-up was 19.3 months, and 22.0% of patients were still receiving avelumab. Among 394 patients (51.0%) who received second-line treatment, the most common was enfortumab vedotin (EV) in 47.0%. Median time to treatment failure (TTF; time from start of avelumab maintenance to discontinuation) was 4.5 months (95% CI 3.8-5.2). Median TTF2 (time from start of avelumab to discontinuation of subsequent treatment) was 10.1 months (95% CI 8.7-11.0). JAVEMACS-D represents the largest real-world dataset of avelumab maintenance therapy for aUC reported to date. Data provide insights about patient characteristics, treatment patterns, and outcomes within an evolving treatment landscape.	bladder
Paradigm shift in the treatment of bladder cancer? The Swedish perspective.	N/A.	bladder
Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.	Immune checkpoint inhibition (ICI) is a promising therapeutic strategy for counteracting tumor immune evasion. The therapeutic response largely depends on interactions between cancer cells and the tumor immune microenvironment (TIME). This study aimed to characterize the TIME and its relationship with the immune checkpoint ligand Programmed Death-Ligand 1 (PD-L1) in canine urothelial carcinomas (UCs). UCs were retrospectively selected and tested for PD-L1 using single-antibody immunohistochemistry. Multiplex immunohistochemistry was performed using anti-CD3, -CD20, and -IBA1 antibodies, to co-localize the immune cells (ICs). Both ICs and PD-L1 expression were quantified with computer-assisted image analysis (QuPath software). Based on the spatial distribution and density of ICs, tumors were classified in three distinct immune phenotypes: immune-inflamed, immune-excluded, and immune-desert. Among the 49 UCs analyzed, 11 (22%) were PD-L1+. Forty carcinomas were classified as immune-inflamed (9 PD-L1+; 31 PD-L1-), 7 as immune-excluded (2 PD-L1+; 5 PD-L1-), and 2 as immune-desert (PD-L1-). Macrophages and T-cells were the most numerous ICs, while B-cells were significantly fewer (p < 0.0001). PDL1 + tumors exhibited a significantly higher number of macrophages compared to PD-L1- tumors (p = 0.003). Immuno-inflamed tumors showed a higher density of T cells (p = 0.01) and a lower macrophages-to-T lymphocytes ratio (p = 0.02) compared to immune-excluded and immune-desert phenotypes. In summary, most UCs were immune-inflamed and T-cell rich; a subset of tumors was PDL1 + and associated with a higher number of macrophages. Further characterization of T lymphocytes and macrophages polarization is necessary to better stratify the immune response.	bladder
Renal ultrasound as a surveillance method for ureteroenteric anastomotic stricture following radical cystectomy and urinary diversion.	OBJECTIVE: To evaluate the performance of short-term renal ultrasound (RUS) as a surveillance tool to detect ureteroenteric anastomotic strictures (UAS) following robot-assisted radical cystectomy (RARC) and extracorporeal urinary diversion (ECUD). METHODS: Patients with bladder cancer who underwent RARC and ECUD at a single tertiary center between October 2011 and August 2022 were included. All patients underwent a planned RUS at 6-weeks postoperatively. A radiologist and a urologist centrally reviewed all images to identify kidneys with hydronephrosis, which was diagnosed based on renal pelvis or calyceal dilation. Renal units with sonographic evidence of hydronephrosis underwent further confirmatory testing using fluoroscopic imaging (loopogram or pouchogram) and nuclear imaging (renal scan with Lasix washout). UAS was confirmed by placing a nephrostomy tube and an antegrade nephrostogram. RESULTS: From a cohort of 392 patients who underwent RARC and ECUD, 316 were included. The median follow-up time was 36.8 months (IQR: 19.5, 78.8). A total of 623 renal units underwent 6-week RUS. Sonographic evidence of hydronephrosis was found in 23% (n = 143) of the units, of which 17% (n = 25) developed UAS. Of the 480 renal units without hydronephrosis, 0.2% (n = 1) developed UAS. 6-week RUS showed 96% and 80% sensitivity and specificity, respectively. The positive and negative predictive values were 17% and 99%, respectively. CONCLUSIONS: A negative 6-week postoperative RUS can strongly predict the absence of UAS, making it a reliable, cost-effective, and non-invasive first-line screening modality to identify patients at a low risk of developing UAS after RARC and ECUD.	bladder
CEACAM6 regulates glycolytic metabolism in bladder cancer cell by controlling ENO1 stability.	BACKGROUND: Bladder cancer (BCa) is one of the most common types of cancers prevalent in the global populace, and it is predominantly detected among men. The role of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in promoting invasion and metastasis in cancers is well known. Despite this, the precise regulatory mechanism by which CEACAM6 contributes to BCa progression remain poorly understood, which is precisely the focus of the present study. METHODS: Our research generated BCa cell lines with CEACAM6 overexpression/knockdown to evaluate the functional significance of CEACAM6. We assessed how the modulation of CEACAM6 influences cell proliferation both in vitro and in vivo on BCa progression. In addition, the effect of CEACAM6 on glycolytic activity was also explored. The co-localization, co-immunoprecipitation, ubiquitination studies, and rescue experiments were performed to understand the molecular interaction between CEACAM6 and alpha-Enolase 1 (ENO1). RESULTS: Our data show that high CEACAM6 expression promotes proliferation, invasion, migration, and clonogenicity of BCa cells. Additionally, CEACAM6 binding to ENO1 and maintain its stability, leading to increased glycolytic activity and invasiveness and proliferative of BCa cells. CONCLUSION: Our study demonstrated that CEACAM6 regulates glycolysis via the ENO1-AKT/mTOR axis. These results offer new evidence about previously unexplored molecular mechanisms driving BCa progression.	bladder
Coptisine regulates PI3K/AKT pathway to block bladder cancer progression: a study based on network pharmacology, in vitro and in vivo assays.	BACKGROUND: Coptisine (COP) is a natural compound extracted from Rhizoma Coptidis, and it represses the malignant biological behaviors of bladder cancer cells. However, the underlying molecular mechanism has not been fully elucidated. The aim of this study was to clarify the downstream mechanism by which COP treats bladder cancer. MATERIALS AND METHODS: SwissTargetPrediction, STITCH, SymMap, ETCM, TCMSP, CTD databases were used to collect the related targets of COP. GeneCards, DisGeNET, TTD and OMIM databases were used to obtain the related targets of bladder cancer. A Venn diagram was used to identify the potential targets of COP in bladder cancer treatment. The protein-protein interaction network was constructed using STRING database, and Cytoscape 3.9.0 software was used to screen the hub targets. The binding relationship between COP and the hub targets was verified by molecular docking and molecular dynamics simulation. After the bladder cell lines T24 and BIU-87 were treated with different doses of COP, the regulatory effects of COP on PI3K/AKT pathway were investigated with western blotting. Additionally, the tumor-suppressive properties of COP on bladder cancer cells were validated with tumorigenesis model and metastasis model in nude mice. RESULTS: RAC-alpha serine/threonine-protein kinase 1 (AKT1), glycogen synthase kinase 3 beta (GSK3B), caspase-3 (CASP3), tumor necrosis factor (TNF) and cyclin D1 (CCND1) were identified as the main hub targets of COP in bladder cancer treatment. PI3K/AKT pathway was predicted to be a crucial pathway regulated by COP. The binding affinities between COP and AKT1, GSK3B, CASP3, TNF and CCND1 were high. COP treatment markedly repressed the phosphorylation level of ERK1/2, AKT1, PI3K p85 and mTOR in T24 and BIU-87 cells, and repressed the tumorigenesis and lung/liver metastasis of T24 cells in vivo. CONCLUSION: COP may be a natural inhibitor for AKT1, GSK3B, CASP3, TNF and CCND1. COP represses PI3K/AKT pathway to suppress the progression of bladder cancer.	bladder
BlaCancer: a mobile health solution for enhancing bladder cancer care.	BACKGROUND: Bladder cancer (BC) ranks among the most prevalent ten cancers globally. Current management for BC has seen limited innovation, particularly for advanced stages. Mobile health (mHealth) technologies offer an opportunity to improve BC management by engaging, educating, and empowering patients and assisting physicians, yet available apps are insufficient. OBJECTIVE: The goal of this study was to provide guidance for designing 'BlaCancer', a mobile app that addresses unfulfilled needs in BC care. We conducted cross-sectional surveys with 16 BC patients and 28 physicians to determine their needs for an mHealth solution. RESULTS: Patients perceived their levele of understanding of BC as moderate (mean score: 4.75/7), and 68.8% supported mobile apps for education, medical records, and peer support. Physicians stressed the significance of treatment recommendations (89.3%), symptom recording (39.3%), and decision-making tools. Other concerns included data privacy and integration issues. CONCLUSION: 'BlaCancer' uses stakeholder input to deliver education, symptom monitoring, and clinical decision assistance. The software intends to increase patient participation, improve communication, and streamline aspects of BC care. The small sample size is a limitation that affects generalizability, but the findings still highlight opinions from physicians and patients regarding the role of an app for BC care. Future research will assess the influence on clinical outcomes and quality of life.	bladder
Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).	OBJECTIVES: To evaluate the rate of left-sided ureteroenteric strictures (UES) following robot-assisted radical cystectomy (RARC) with a retrosigmoid ileal conduit compared to a conventional ileal conduit in a randomised controlled trial (RCT). PATIENTS AND METHODS: This multicentre, RCT included 303 patients undergoing RARC between May 2020 and August 2022. Patients were randomised to receive either a retrosigmoid or a conventional ileal conduit. Analyses were performed an intention-to-treat basis. RESULTS: Of the 149 patients randomised for the retrosigmoid ileal conduit, a total of 137 (92%) patients received the allocated conduit. In the control group, 150 of 154 (97.4%) patients underwent RARC and one patient was lost to follow-up. At a median follow-up of 754 days, the rate of left-sided UES was 4.1% (six of 148) in the intervention group and 6.7% (10 of 149) in the control group (P = 0.31). No significant differences were observed in postoperative creatinine clearance or metabolic complications, including vitamin B(12) deficiency and metabolic acidosis. CONCLUSION: The rate of left-sided UES was not significantly reduced with the retrosigmoid conduit compared to the conventional approach. However, the procedure was feasible without increased risk of metabolic complications and therefore may be a good alternative when extensive resection of the left ureter is needed.	bladder
Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer risk? A meta-analysis.	BACKGROUND: We still do not know the exact cause of bladder cancer (BC). OBJECTIVES: Evaluation of the effect of TP53 Arg72Pro and MDM2 T309G polymorphisms with the risk of Bladder cancer. METHODS: A literature search was conducted followed by a meta-analysis. Then, sensitivity and subgroup analyses were performed. 14 relevant studies were included in the quantitative analysis. RESULTS: No statistically significant associations were found. The results of the subgroup analysis revealed a significant association in the Turkish population for T309G: G vs. T (P-value= 0.015; OR 95%CI= 1.51 [1.084; 2.125]), GG vs.TT (P-value= 0.009; OR 95% CI= 2.60 [1.262; 5.370]). Sensitivity analysis revealed a significant association between the Arg72Pro: C vs. G (OR= 1.22, 95% CI [1.05; 1.40]), CC vs. GG (OR= 1.54; 95% CI [1.13; 2.09]), CC+CG vs. GG (OR= 1.24; 95% CI [1.01; 1.53]), CC vs. CG+GG (OR= 1.33; 95% CI [1.01; 1.74]), and T309G: G vs. T (OR= 1.30; 95% CI [1.07; 1.57]), GG vs. GT+TT (OR= 1.53; 95% CI [1.10; 2.11]), GG vs. GT (OR=1.44; 95% CI [1.02; 2.02]), GG vs. TT (OR= 1.88; 95% CI [1.25; 2.82]) with BC occurrence. CONCLUSION: The T309G polymorphism was found to be a predisposing allele for BC in Turkish population.	bladder